{
    "2020-02-05": [
        [
            {
                "time": "2023-01-15",
                "original_text": "Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market",
                "features": {
                    "keywords": [
                        "NASH",
                        "Drug",
                        "Candidates",
                        "Market"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-01-15",
                "original_text": "Novo Nordisk (NVO) Q4 Earnings Match Estimates, Revenues Beat",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Q4",
                        "Earnings",
                        "Revenues",
                        "Beat"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-01-15",
                "original_text": "The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data",
                "features": {
                    "keywords": [
                        "Merck",
                        "Spins Off",
                        "Slow-Growth",
                        "Businesses",
                        "ZioPharm",
                        "Offering",
                        "PhaseBio",
                        "Data"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}